Central Asia Drug Action Programme –Phase 6 (CADAP 6)
CADAP 6 supports the drug demand aspect of a balanced drug policy in line with the EU Drug Strategy 2013-2020 and the EU Central Asia Drug Action Plan 2014-2020 and assists the Central Asian governments in strengthening the capacity of national agencies to deal with the drug phenomenon in a comprehensive, integrative, and sustainable manner. All programme activities under CADAP 6 focus both on national and regional capacity building by providing policy advice and technical assistance, monitoring of the drugs situation, prevention, drug treatment and harm reduction services.
Start: 01 April 2015
Duration: 36 months
Implemented by a Consortium of EU institutions: Trimbos Institute (the Netherlands), ResAd (Czech Republic), National Bureau for Drug Prevention (Poland), and Frankfurt University of Applied Sciences (Germany) led by Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH.
Facts and figures
Start: 01 April 2015
Duration: 54 months
Budget: EUR 9,057,333 (EUR 6,533,333 EU, EUR 2,524,000 BMZ)
In alliance with the EU’s balanced drug policy principles, related standards and practices and in line with the EU Drug Strategy (2013-2020) and the EU-Central Asia Drug Action Plan (2014-2020), the overall objective of CADAP 6 is to strengthen the capacity in the five Central Asian countries to deal with the drug phenomenon in the region in a comprehensive, integrative and sustainable manner.
Specific objectives and expected results
|Specific objectives:||Components:||Expected results:|
|To enrich national authorities’ knowledge about the EU balanced drugs policy and different national strategies implemented in EU countries, assist willing governments in CA with the review of old and drafting of new National Strategies, Action Plans and drug legislation and assist other relevant stakeholders in CA with identifying and reaching consensus on drug policy needs and priorities.||▶||
National Drug Strategy (NDS)
|▶||The knowledge and capacity of the national policy makers in new methodologies for preparing balanced national strategies and policies is increased and strategies, action plans and legislation employing European good practices are adopted and implemented.|
|To support all five countries in acquiring a comprehensive approach of data collection and data-supported decision and policy making, using models and standards developed and promoted by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)||▶||
National Focal Point (NFP)
|▶||National authorities (decision and policy makers) are better informed about the drug situation in the country through a well-established information network and data collection, and thus the capacity for taking relevant and informed decisions is improved.|
|To support all CA countries in their prevention programmes and actions employing European best practices and international standards.||▶||
|▶||Healthcare and social responses for tackling drug use in the region are increased by promoting social awareness on drugs further.|
|To support all CA countries in their treatment and harm reduction programmes and actions employing European best practices and international standards.||▶||
|▶||Healthcare and social responses for tackling drug use in the region are increased by consolidating best practices and better quality services for drug users.|
The final beneficiaries of the programme include policy makers, drug experts, teachers, media professionals, penitentiary and hospital staff, psychologists, therapists, social workers, general public, drug users, prisoners and generally young people.